[Autoantibodies to glutamate receptor subtypes--markers of functional brain damage: their diagnostic significance for detecting paroxysmal activity and ischemia].

A new direction in diagnostics and the control of pharmacological treatment of brain disorders is discussed. Problems which are considered in the review have significance for understanding the neurochemical mechanisms of paroxysmal activity and brain ischemic stroke. The identification of autoantibodies for glutamate receptors, thought to be involved in these brain disorders, presents a new approach toward characterization of clinical states of individuals and could have a wide application for control of efficiency of pharmacological treatments.